Chromadex Corp logo

CDXC

Chromadex Corp

$1.64

Earnings Summary

Revenue
$17.26Mn
Net Profits
$-7.74Mn
Net Profit Margins
-44.85%

Highlights

Revenue:

Chromadex Corp’s revenue jumped 17.54% since last year same period to $17.26Mn in the Q1 2022. On a quarterly growth basis, Chromadex Corp has generated 200.06% jump in its revenue since last 3-months.

Net Profits:

Chromadex Corp’s net profit fell -4.86% since last year same period to $-7.74Mn in the Q1 2022. On a quarterly growth basis, Chromadex Corp has generated -45.35% fall in its net profits since last 3-months.

Net Profit Margins:

Chromadex Corp’s net profit margin jumped 10.79% since last year same period to -44.85% in the Q1 2022. On a quarterly growth basis, Chromadex Corp has generated -245.26% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Chromadex Corp post its latest quarter earnings

EPS Estimate Current Quarter
-0.08
EPS Estimate Current Year
-0.08

Highlights

EPS Estimate Current Quarter:

Chromadex Corp’s earning per share (EPS) estimates for the current quarter stand at -0.08 - a 11.11% jump from last quarter’s estimates.

EPS Estimate Current Year:

Chromadex Corp’s earning per share (EPS) estimates for the current year stand at -0.08.

Key Ratios

Key ratios of the Chromadex Corp post its Q1 2022 earnings

Earning Per Share (EPS)
-0.11
Return on Assets (ROA)
-0.31
Return on Equity (ROE)
-0.9
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Chromadex Corp’s earning per share (EPS) jumped 8.33% since last year same period to -0.11 in the Q1 2022. This indicates that the Chromadex Corp has generated 8.33% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Chromadex Corp’s return on assets (ROA) stands at -0.31.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Chromadex Corp’s return on equity (ROE) stands at -0.9.

Dividend Per Share (DPS):

Chromadex Corp declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.09
-0.11
-22.22%

Company Information

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®.

Organisation
Chromadex Corp
Headquarters
Los Angeles, California, United States
Employees
110
Industry
Process Industries
CEO
Robert Fried